Neurosave

Print

“FAB117-HC, NEW ALLOGENIC CELLULAR MEDICINE FOR THE TREATMENT OF PATIENTS WITH ACUTE TRAUMATIC SPINAL INJURY: REGULATORY STUDY PHASE I / II”

neurosave

Call identifier: Proyectos de I+D en Cooperación Nacional

Reference Nº: IDI-20151267

Subsidised by the Center for Industrial Technological Development (CDTI), within the framework of the call 'Research Project and Development in Cooperation'.

Within the framework of this project, the companies FERRER INTERNACIONAL, S.A. (FERRER) and HISTOCELL, S.L. (HISTOCELL) have decided to join forces and resources to carry out the phase I / IIA clinical development of a new drug based on the use of modified adult mesenchymal stem cells. This medicine allow reducing the injury in the acute phase, improving the prognosis of chronic patients and, consequently, the expense what entails for patients and their families, the National Health System and other institutions dedicated to this end. This project represents a great technological challenge that the companies could not carry out separately, but its success is guaranteed thanks to the experience of both in the development of drugs.

The project started in July 2015 and will continue in development until the end of 2019.